Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical Trial
Table 2
Mean VSS scores during 12 weeks of follow-up.
Outcomes
Time points
TriamHEXAL
TriamHEXAL + Avastin
Changes
Mean
SD
Mean
SD
Mean (95% CI)
Height
Baseline
2.00
0.47
2.05
0.40
−0.05 (−0.34, 0.24)
0.817
Month 1
1.26
0.65
1.18
0.81
0.09 (−0.41, 0.58)
0.661
Baseline-month 1
0.74
0.56
0.82
0.64
−0.09 (−0.49, 0.32)
0.667
Month 3
1.00
0.67
0.94
0.90
0.06 (−0.47, 0.59)
0.684
Baseline-month 3
1.00
0.47
1.06
0.75
−0.06 (−0.49, 0.37)
0.783
<0.001
<0.001
Vascularity
Baseline
2.47
0.77
2.58
0.77
−0.11 (−0.61, 0.40)
0.644
Month 1
0.83
0.51
0.94
0.56
−0.11 (−0.48, 0.26)
0.660
Baseline-month 1
1.72
0.83
1.59
0.51
0.13 (−0.34, 0.61)
0.570
Month 3
0.83
0.51
0.59
0.62
0.25 (−0.15, 0.64)
0.245
Baseline-month 3
1.72
0.67
1.94
0.66
−0.22 (−0.68, 0.24)
0.337
<0.001
<0.001
Pliability
Baseline
2.95
0.78
3.05
0.78
−0.11 (−0.62, 0.41)
0.680
Month 1
1.79
1.03
1.75
1.18
0.04 (−0.72, 0.80)
0.917
Baseline-month 1
1.16
0.60
1.31
0.79
−0.15 (−0.63, 0.33)
0.517
Month 3
1.53
0.96
1.19
1.28
0.34 (−0.43, 1.11)
0.378
Baseline-month 3
1.42
0.61
1.88
0.96
−0.45 (−1.00, 0.09)
0.098
<0.001
<0.001
Pigmentation
Baseline
2.00
0.00
2.00
0.00
0.00
1
Month 1
1.37
0.83
1.41
0.71
−0.04 (−0.57, 0.48)
1
Baseline-month 1
0.63
0.83
0.59
0.71
0.04 (−0.48, 0.57)
0.868
Month 3
1.42
0.84
0.82
0.88
0.60 (0.01, 1.18)
0.066
Baseline-month 3
0.58
0.84
1.18
0.88
−0.60 (−1.18, −0.01)
0.045
0.003
<0.001
Total score
Baseline
9.42
1.61
9.53
1.46
−0.11 (−1.15, 0.94)
0.835
Month 1
5.21
2.46
5.18
2.79
0.03 (−1.74, 1.81)
0.969
Baseline-month 1
4.21
2.02
4.35
1.62
−0.14 (−1.39, 1.11)
0.818
Month 3
4.74
2.42
3.47
3.14
1.27 (−0.62, 3.16)
0.182
Baseline-month 3
4.68
1.77
6.06
2.08
−1.37 (−2.68, −0.07)
0.039
<0.001
<0.001
: value obtained to compare means between treatment groups; : value obtained to compare means within treatment groups. The significance of values is <0.05.
